Advanced Technology Intraocular Lens Utilization in Eyes with Glaucoma and Diabetic Retinopathy Across US Academic Centers: Analysis of the SOURCE Repository
This multicenter retrospective study of over 250,000 cataract surgeries across US academic centers reveals that while advanced technology intraocular lens (ATIOL) utilization has increased significantly since 2009, it remains substantially lower for patients with glaucoma or diabetic retinopathy—particularly as disease severity increases—and is marked by persistent disparities based on language and race.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine a world where the simple act of removing a cloudy lens from the eye, a procedure known as cataract surgery, could do more than just restore clear vision. For decades, the goal was merely to see again. Today, however, surgeons can offer lenses that do more than that. These advanced lenses, often called high-tech lenses, can correct the natural loss of focus that comes with aging, allowing patients to see clearly at near, intermediate, and far distances without needing glasses. They can also fix the irregular curvature of the eye that causes astigmatism. While these options promise a life with less dependence on eyewear, they are not a one-size-fits-all solution. The human eye is a complex system, and when it is already struggling with other diseases, such as high pressure damaging the optic nerve or diabetes affecting the retina, the decision to use these sophisticated lenses becomes much harder. Surgeons must weigh the potential for better vision against the risk that the eye's underlying disease might limit the benefit or cause new problems.
A large team of researchers set out to understand how this decision is actually made in the real world. They looked at the records of more than 250,000 cataract surgeries performed at sixteen major university medical centers across the United States over a fifteen-year period. Their goal was to see who was getting these advanced lenses and who was not, specifically focusing on patients who also had glaucoma or diabetic retinopathy. They wanted to know if the presence of these diseases changed the choice of lens, and whether factors like a patient's race, language, or income played a role in the decision. The researchers found that while the use of these high-tech lenses has grown significantly over time, rising from about 5 percent of surgeries in the early years to over 21 percent in recent years, the pattern of who receives them is far from uniform.
The study revealed a clear trend: patients with eye diseases were much less likely to receive these advanced lenses than patients with healthy eyes. Only about 10 percent of patients with glaucoma and roughly 7 percent of those with diabetic retinopathy received a high-tech lens, compared to 13 percent of patients without these conditions. This gap widened as the disease got worse. For patients with severe glaucoma or advanced diabetic retinopathy, the use of these lenses dropped even further. The researchers also looked at a specific type of lens designed only to fix astigmatism, which does not split light like the other advanced lenses do. Even for this simpler option, patients with eye diseases were less likely to receive it, suggesting that the hesitation is not just about the complex optics of the lens, but perhaps about the overall health of the eye or the perceived value of the surgery for that specific patient.
Beyond the medical conditions, the study uncovered deep divides based on who the patient was. Language emerged as one of the strongest factors. Patients who spoke English were more than twice as likely to receive an advanced lens compared to those who spoke another language. Race also played a significant role; Black patients were far less likely to receive these lenses than White patients, and similar disparities existed for Hispanic patients and those with different insurance types or employment statuses. Patients with commercial insurance or those who were employed were more likely to get the advanced lenses than those on public insurance or those who were disabled. The researchers noted that while cost is a known barrier, as these lenses often require extra payment, the language and racial gaps suggest that communication and access to information are also major hurdles.
The authors of the study emphasize that their work does not prove that these decisions were right or wrong, only that they happened. They could not see the private conversations between doctors and patients or know the specific reasons a surgeon chose one lens over another. However, the data paints a picture of a medical landscape where access to the latest technology is not equal. The variation was so great that some hospitals performed these advanced surgeries in less than 1 percent of cases, while others did so in more than 80 percent. This suggests that local habits and the comfort level of individual surgeons play a massive role, perhaps more than the specific needs of the patient. The findings point to a need for clearer guidelines on who should receive these lenses, especially for those with complex eye diseases, and a need to ensure that all patients, regardless of their background or language, have the same opportunity to discuss and choose the best vision for their future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.